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Summary
Background—Stromal interaction molecule 1 (STIM1) was recently identified as a critical
component of store-operated calcium entry (SOCE) in platelets. We previously reported the Ca2+-
sensing guanine nucleotide exchange factor CalDAG-GEFI as critical molecule in Ca2+ signaling
in platelets.
Objective—To evaluate the contribution of STIM1/SOCE to Ca2+-dependent platelet activation
and thrombosis, we here compared the activation response of platelets lacking STIM1 and
platelets lacking CalDAG-GEFI.
Methods—The murine Stim1 gene was conditionally deleted in the megakaryocyte/platelet
lineage. CalDAG-GEFI−/− and Stim1fl/fl PF4-Cre along with littermate control mice were used
for in vitro and in vivo experiments under flow as well as static conditions.
Results—αIIbβ3-mediated aggregation was markedly impaired in CalDAG-GEFI- but not
STIM1-deficient platelets, both under static or flow conditions. In contrast, deficiency in either
STIM1 or CalDAG-GEFI significantly impaired the ability of platelets to express phosphatidyl
serine on the cell surface. When subjected to a laser injury thrombosis model, mice lacking STIM1
in platelets were characterized by the formation of unstable platelet-rich thrombi and delayed and
reduced fibrin generation in injured arterioles. In CalDAG-GEFI−/− mice, fibrin generation was
also delayed and reduced, but platelet accumulation was virtually abolished.
Conclusions—Our studies suggest that 1) STIM1/SOCE is critical for the pro-coagulant activity
but not the pro-adhesive function of platelets, and 2) at the site of vascular injury, STIM1 and
CalDAG-GEFI are critical for the first wave of thrombin generation mediated by pro-coagulant
platelets.
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Platelet activation is triggered by various agonists including subendothelial collagens, the
second wave mediators adenosine diphosphate (ADP) and thromboxane A2 (TxA2), and the
protease thrombin [1]. ADP, thrombin and TxA2 stimulate platelets via specific G protein-
coupled receptors (GPCR), while collagen signals via the immunoglobulin-like receptor
glycoprotein (GP) VI and an immunoreceptor tyrosine activation motif (ITAM) within the
associated Fc receptor γ chain. Independent of the activating receptor, cellular stimulation
leads to the activation of phospholipase C and the subsequent mobilization of the second
messengers calcium (Ca2+) and diacylglycerol (DAG). DAG is critical for protein kinase C
(PKC) activation, a key event in platelet granule release and integrin activation [2]. Ca2+
regulates various adhesive platelet responses such as integrin activation and the release of
ADP and TxA2 [1, 3, 4]. Furthermore, sustained increases in the intracellular calcium
concentration ([Ca2+]i) are critical for the ability of platelets to switch from a pro-adhesive
to a pro-coagulant state [5, 6]. Crucial to this conversion is the scrambling of phosphatidyl
serine (PS) from the inner to the outer membrane leaflet, a process that is mediated by
transmembrane protein 16F [7]. The surface-exposed PS provides a negatively charged
surface for the assembly of factors and cofactors of the prothrombinase (FXa and FVa)
complex, resulting in a potent enhancement of thrombin/fibrin generation. Strong platelet
activation also mobilizes FV/FVa from granular stores, making it available for incorporation
into the prothrombinase complex [8].
In our recent work, we identified the guanine nucleotide exchange factor, CalDAG-GEFI, as
a critical molecule in Ca2+ signaling in platelets [9–12]. CalDAG-GEFI activates the small
GTPase Rap1, a central molecular switch that drives platelet activation by directly
regulating integrin-mediated aggregation [9,12,13] and the release of autocrine agonists
[11]. CalDAG-GEFI-independent activation of Rap1 requires signaling by PKC and the Gi-
coupled receptor for ADP, P2Y12. Platelets lacking CalDAG-GEFI are severely impaired in
their ability to aggregate and to adhere to sites of vascular injury [14].
An increase in the [Ca2+]i can derive from two main sources: release of Ca2+ from
intracellular stores and Ca2+ entry through the plasma membrane (PM). Store release
depends on the formation of inositol 1,4,5-triphosphate (IP3) by PLC, which triggers the
activation of IP3 receptors and thus opening of the pore. Calcium entry through the PM is
directly coupled to store release by a mechanism called store operated Ca2+ entry (SOCE).
Stromal interaction molecule 1 (STIM1) and Orai1 were recently identified as two main
players in SOCE [15–19]. STIM1 is a trans-membrane protein containing two EF hand
domains that are situated in the lumen of the endoplasmic reticulum (ER). Upon store
depletion, Ca2+ dissociates from the EF hand domain of STIM1, leading to co-localization
of STIM1 and the PM membrane channel moiety, Orai1, and subsequent Ca2+ entry through
the PM.
Recent studies in mice lacking functional STIM1 or Orai1 demonstrated a key role for both
proteins in SOCE in platelets [20–23]. Observations common to these studies were the
virtually abolished Ca2+ entry in response to physiological and non-physiological agonists,
and the moderate defects in integrin activation and granule release observed in mutant
platelets. Discrepant results, however, were observed with regard to the importance of
SOCE for thrombus formation under physiological flow conditions [23]. While platelet
adhesion to collagen was significantly reduced in blood from chimeric mice lacking STIM1
or Orai1 in blood cells only, normal thrombus formation was observed under similar
experimental conditions for platelets expressing an inactive mutant of Orai1 [22]. In the
latter studies, we further suggested that SOCE is critical for the pro-coagulant but not the
pro-adhesive role of Ca2+ in platelet activation.
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In the current study, we compared the platelet activation response in mice with a conditional
deletion of STIM1 in platelets/megakaryocytes and mice lacking CalDAG-GEFI, both in
vitro and in vivo. The main conclusions from our studies are: (1) STIM1/SOCE is not
critical for the pro-adhesive role of Ca2+ in platelet activation, (2) PS exposure and fibrin
generation at a site of vascular injury are dependent to a similar degree on STIM1 and
CalDAG-GEFI, (3) the conversion from a pro-adhesive to a pro-coagulant platelet requires
signaling via the small GTPase Rap1, and (4) platelet-dependent thrombin/fibrin generation
is critical for thrombus stability and growth in vivo.
Material and Methods
Materials
Low molecular weight Lovenox (enoxaparin sodium; Sanofi-Aventis, Bridgewater, NJ),
heparin-coated capillaries (VWR, West Chester, PA), bovine serum albumin (BSA, fraction
V), prostacyclin (PGI2), and human fibrinogen (type I) (all from Sigma-Aldrich, St Louis,
MO), 2-methylthio-AMP triethylammonium salt hydrate (2-MeSAMP, P2Y12 inhibitor,
BioLog, Bremen, Germany), fibrillar collagen type I (Chronlog, Havertown, PA),
polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA), annexin V
(Invitrogen Corporation, Carlsbad, CA), and PAR4-activating peptide (Advanced Chemtech,
Louisville, KY) were purchased. Convulxin and collagen-related peptides (CRP) were
provided by Kenneth Clemetson (Theodor Kocher Institute, University of Berne,
Switzerland) and Richard Farndale (University of Cambridge, Cambridge, UK),
respectively. Antibodies directed against the activated form of murine αIIbβ3, JON/A-PE,
GPIX (Emfret Analytics, Wuerzburg, Germany), β1 integrin and P-selectin (BD
Biosciences, Chicago, IL), von Willebrand factor (VWF) and fibrinogen (Dako, Carpinteria,
CA) were purchased.
Mice
Stim1fl/fl Pf4-Cre [24], CalDAG-GEFI−/− [9] and littermate control mice were bred in the
mouse facility of Thomas Jefferson University. Experimental procedures were approved by
the Animal Care and Use Committee of Thomas Jefferson University.
Blood collection and platelet preparation
Blood was drawn from the retroorbital plexus into heparinized tubes. Platelet rich plasma
(PRP) was prepared by centrifugation of heparinized blood at 100g for 5 minutes. Platelets
were washed twice with modified Tyrode’s buffer (137 mM NaCl, 0.3 mM Na2HPO4, 2mM
KCl, 12 mM NaHCO3, 5 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid, 5 mM
glucose, pH 7.3) in the presence of PGI2 by centrifugation at 700g and re-suspended in
Tyrode’s buffer at concentration of 4 × 108 platelets/ml.
Flow cytometry
Ca2+ flux measurement—Washed platelets diluted in Tyrode’s buffer were loaded with
10 µM Fluo-4 for 10 minutes. Platelets were activated with the indicated agonists in the
presence of 0.5 mM CaCl2 and immediately analyzed by flow cytometry.
STIM1 expression in platelets and leukocytes—400 µl heparinized whole blood was
lysed in 3,600 µl red cell lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2-
EDTA pH 7.3) for 10 minutes at room temperature (RT). The lysed cells were centrifuged at
400g and the supernatant was discarded carefully. The pellet was re-suspended in 400 µl
PBS and 44 µl of formaldehyde (37%) was added for 10 minutes. The cells were washed
with PBS, the supernatant was discarded carefully and the pellet was incubated for 5
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minutes with 0.5% Triton. After a washing step with PBS containing 1% BSA, the cells
were incubated with rabbit anti-STIM1 (2 µg/ml) or rabbit anti-VWF (2 µg/ml) for 10
minutes, washed once in PBS/BSA, and stained with anti-Mac1-PE (2 µg/ml) or anti-
CD41b-PE (2 µg/ml) along with anti-rabbit-Alexa488 (10’, RT). Cells were immediately
analyzed by flow cytometry.
Expression levels of platelet surface receptors and intracellular proteins—
Washed platelets were stained with FITC-labeled antibodies to GPVI, GPIX, αIIbβ3, or β1
integrin and immediately analyzed on a FACScalibur. For the detection of intracellular
proteins, washed platelets were fixed and permeabilised as described above, stained with
FITC-labeled antibodies to VWF, fibrinogen, or P-selectin, and immediately analyzed.
αIIbβ3 activation and P-selectin expression—Platelets were washed and diluted with
Tyrode’s containing 1 mM CaCl2, activated with different doses of PAR4p or Cvx for 10
minutes in the presence or absence of the P2Y12 inhibitor 2-MeSAMP (100 µM), and
stained for activated αIIbβ3 (JON/A-PE) and P-selectin expression (α-Pselectin-FITC).
Phosphatidyl-serine exposure—Platelets were stimulated in Tyrode’s buffer
containing 2 mM CaCl2 with different doses of Cvx along with 100 µM of PAR4p in the
presence or absence of 2-MeSAMP. Cells were stained with annexin V-Alexa647 (2 µg/ml)
for 10 minutes at RT and immediately analyzed by flow cytometry.
Flow chamber studies
In vitro flow studies were performed in a microfluidic device fabricated in poly
dimethylsiloxane (PDMS). Fabrication of microfluidic devices and microfluidic collagen
patterning were performed as previously described [25]. Briefly, a 100 µm-strip of fibrillar
collagen type I (200 µg/ml) was deposited and immobilized by microfluidic patterning along
the length of a glass slide. A PDMS device with 10 flow channels (width: 250 µm, hight: 60
µm, length: 6 mm) was oriented perpendicular to the patterned collagen. Murine whole
blood was drawn from the retro-orbital plexus into heparinized tubes (30 U/ml Lovenox),
incubated with 1.5 µg/ml of anti-GPIX-Alexa488 and annexinV-Alexa647 (1 µg/ml), and
infused at arterial (1700-S) or venous (400-S) wall shear rates for 5 minutes. Adhesion of
platelets was monitored continuously with a Nikon Ti-U inverted microscope (Nikon
Instruments Inc., Melville, NY) equipped with a Retiga EXL monochrome camera
(QImaging, Surrey, Canada). Images were analyzed using Nikon NIS Elements software
(NIS-Elements Advanced Research; Melville, NY, USA).
Aggregometry
Platelet rich plasma (PRP) was obtained from heparinized blood. PRP was washed twice and
count was adjusted to 3 × 108 platelets/ml with modified tyrodes buffer. Indicated doses of
various agonists were added and transmission was recorded over 10 minutes on a Chrono-
log 4-channel optical aggregation system (Chrono-log, Havertown, PA).
Western blotting
Platelet lysates were separated by 4% to 12% gradient sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to PVDF membranes. STIM1 was
detected with a rabbit polyclonal antibody raised against the C-terminal domain of STIM1
with a conserved 29-amino acid peptide [26]. After incubation with horseradish peroxidase-
coupled anti–rabbit antibodies (Vector Laboratories), immunoreactivity was detected by
Western Lightning enhanced chemiluminescence (G-Biosciences).
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Laser-injury induced thrombosis in cremaster muscle
Laser-induced thrombosis in the cremaster muscle microcirculation was performed as
described previously [27, 28]. Briefly, male mice (12–14 weeks of age) were
intraperitoneally injected with sodium pentobarbital (11 mg/kg, Abbott Laboratories), and
maintained under anesthesia with the same anesthetic delivered via the catheterized jugular
vein as described previously. The cremaster muscle was isolated and the microvessels
studied using an Olympus BX61WI microscope (Olympus, Center Valley, PA, USA) with a
40×/0.8 numeric aperture water-immersion objective lens. Laser injuries were done using an
SRS NL100 Nitrogen Laser system (Photonic Instruments, Saint Charles, IL, USA) at 65%
energy level. 5 min prior to injury, mice were injected intravenously with Alexa488-coupled
Fab fragments of MWReg30, an antibody directed against murine αIIbβ3 (0.2 µg/g body
weight, BD Pharmingen), and Alexa647 conjugated murine anti-fibrin antibody (0.45 µg/g).
No more than 5 arterioles were studied per mouse. All data were analyzed using Slidebook
4.2 software (Intelligent Imaging Innovations Philadelphia, PA, USA).
Statistics
Results are reported as mean ± SEM and statistical significance was assessed by unpaired 2-
tailed Student t test. A P value less than 0.05 was considered significant.
Results
Generation of Stim1fl/fl Pf4-Cre mice
Stim1fl/fl mice were generated as described recently [24]. Stim1fl/fl mice were crossed with
Pf4-Cre mice [29] to delete the Stim1 gene in the megakaryocyte/platelet lineage.
Deficiency in platelet STIM1 was confirmed by western blotting and flow cytometry.
STIM1 protein was detectable in lysates of Stim1fl/fl but not Stim1fl/fl Pf4-Cre platelets (Fig.
1A). Intracellular staining for STIM1 in platelets and Mac1-positive leukocytes
demonstrated specific deletion in Stim1fl/fl Pf4-Cre platelets (Fig. 1B). Von Willebrand
factor, a protein stored in alpha granules of platelets, was present in both Stim1fl/fl and
Stim1fl/fl Pf4-Cre platelets. Specific deletion of STIM1 in platelets did not affect peripheral
platelet counts or platelet size (not shown). No difference was observed between Stim1fl/fl
and Stim1fl/fl Pf4-Cre platelets with regard to (a) the surface expression of platelet receptors
GPVI, GPIX, αIIbβ3, and β1 integrins (Table 1) and (b) the cellular levels of important
platelet proteins such as VWF, fibrinogen, or P-selectin (Table 2).
Impaired store operated calcium entry (SOCE) in STIM1 deficient platelets
First, we determined the effect of STIM1 deficiency on SOCE in platelets. Stim1fl/fl and
Stim1fl/fl Pf4-Cre platelets were loaded with the calcium sensing dye Fluo-4 and treated with
the sarcoplasmic reticulum Ca2+ATPase (SERCA) pump inhibitor thapsigargin (TG, 5 µM)
in the absence of extracellular calcium (Fig. 1C). Upon addition of extracellular calcium,
rapid influx of Ca2+ was observed in Stim1fl/fl but not in Stim1fl/fl Pf4-Cre platelets.
Calcium flux was also studied in platelets activated via the thrombin receptor, PAR4, or the
collagen receptor, GPVI. Cellular stimulation with high doses of PAR4-activating peptide
(PAR4p, supplemental Fig. 1A) or the GPVI agonist convulxin (Cvx, supplemental Fig. 1B)
led to a rapid, sustained increase in [Ca2+]i in Stim1fl/fl platelets. In stimulated Stim1fl/fl Pf4-
Cre platelets, however, [Ca2+]i rose rapidly but dropped back to baseline within a few
minutes, presumably due to impaired Ca2+ entry into the cell. A more prominent defect in
Ca2+ mobilization was observed in Stim1fl/fl Pf4-Cre platelets activated with low doses of
PAR4p or Cvx, suggesting that STIM1-mediated SOCE is crucial for calcium flux under
conditions of weak platelet activation. Confirming this hypothesis, we observed the
strongest defect in calcium mobilization in Stim1fl/fl Pf4-Cre platelets activated with
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collagen-related peptides (supplemental Fig. 1C), a GPVI-specific agonist with weaker
activating activity than Cvx.
Contribution of STIM1 and CalDAG-GEFI to Ca2+-dependent platelet activation,
aggregation, and thrombus formation in vitro
To evaluate the contribution of STIM1 to Ca2+-dependent platelet activation, we compared
αIIbβ3 integrin activation and alpha granule release in stimulated Stim1fl/fl Pf4-Cre and
CalDAG-GEFI−/− platelets. Stim1fl/fl Pf4-Cre platelets activated with PAR4p (supplemental
Fig. 2A) or Cvx (supplemental Fig. 2B) showed a significant reduction in αIIbβ3 activation
and P-selectin expression (a measure for alpha granule release) at low and high doses of the
agonists when compared to controls. Stim1fl/fl Pf4-Cre platelets showed a normal
aggregation response when activated with PAR4p or Cvx and a mild aggregation defect
upon stimulation with type-I fibrillar collagen or CRP (Fig. 2). In contrast, CalDAG-GEFI−/
− platelets have a documented aggregation defect when activated with low doses of PAR4p
[10] or Cvx [11], and they failed to aggregate in response to all tested concentrations of
collagen or CRP. As we recently demonstrated, platelet aggregation in the absence of Ca2+/
CalDAG-GEFI requires signaling via the Gi-coupled receptor for ADP, P2Y12 [10]. To
evaluate the contribution of SOCE to CalDAG-GEFI-dependent platelet activation, we
stimulated Stim1fl/fl Pf4-Cre platelets in the presence of a P2Y12 inhibitor, 2-MeSAMP.
Compared to 2-MeSAMP-treated control platelets, PAR4p or Cvx-induced αIIbβ3 activation
of P2Y12-treated Stim1fl/fl Pf4-Cre platelets was significantly reduced at all tested agonist
concentrations (supplemental Fig. 3A, C). Similarly, degranulation as measured by surface
expression of P-selectin was significantly reduced in 2-MeSAMP-treated Stim1fl/fl Pf4-Cre
platelets (supplemental Fig. 3B).
Consistent with the activation/aggregation studies, thrombus formation in Stim1fl/fl Pf4-Cre
blood perfused over collagen at arterial (1700-S) or venous (400-S) shear rates was normal
when compared to controls (Fig. 3A,B,C). In contrast, CalDAG-GEFI−/− platelets were
unable to form three-dimensional thrombi under the same experimental conditions (Fig. 3A,
lower panel), confirming recent results [14]. Thus, STIM1-mediated SOCE contributes little
to the adhesive function of platelets, both under static and flow conditions.
STIM1 and CalDAG-GEFI are critical for platelet phosphatidylserine exposure and fibrin
generation in vivo
Aside of integrin activation and granule release, calcium plays a crucial role for
phosphatidyl serine (PS) exposure and the pro-coagulant response in activated platelets [7,
22, 23]. To test the ability of Stim1fl/fl Pf4-Cre or CalDAG-GEFI−/− platelets to express PS
upon stimulation, we quantified PS exposure during perfusion of Stim1fl/fl Pf4-Cre blood
over collagen (Fig. 4A) and by flow cytometry after stimulation with PAR4p and Cvx (Fig.
4B). In both assays, significantly less PS-positive Stim1fl/fl Pf4-Cre platelets were observed
when compared to controls. Interestingly, the defect in PS exposure in stimulated CalDAG-
GEFI−/− platelets was similar to that of Stim1fl/fl Pf4-Cre platelets, suggesting that
sustained increased [Ca2+]i leads to PS exposure via signaling through CalDAG-GEFI/
Rap1. Furthermore, we observed that PS exposure was completely inhibited in CalDAG-
GEFI−/− platelets pretreated with a P2Y12 inhibitor (Fig. 4C), i.e. platelets with abolished
Rap1 signaling [10, 11]. Similarly, P2Y12 inhibition further reduced PS exposure in
Stim1fl/fl Pf4-Cre platelets. Together these studies suggested that the previously described
anti-thrombotic phenotype of mice lacking functional platelet STIM1 may be due to an
impaired contribution of platelets to thrombin generation at the site of injury rather than an
impaired adhesive ability of these cells.
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To compare the contribution of STIM1 and CalDAG-GEFI to thrombin generation and
thrombus formation in vivo, we measured fibrin generation and platelet accumulation in
arterioles damaged by laser injury. Compared to controls, accumulation of Stim1fl/fl Pf4-Cre
platelets was significantly reduced, confirming previous results [21]. When looking at the
kinetics of platelet accumulation, we observed that the initial phase of platelet accumulation
was not affected in Stim1fl/fl Pf4-Cre mice. Early thrombi, however, were reversible and in
most cases disappeared within one minute after laser injury (Fig. 5A,C). Interestingly, we
also observed a marked delay and reduction in fibrin generation in injured arterioles of
Stim1fl/fl Pf4-Cre mice, suggesting that STIM1 plays an important role for platelet-
dependent thrombin/fibrin generation in the early phase of thrombus formation. A similar
delay and reduction in fibrin generation was observed in CalDAG-GEFI−/− mice. Platelet
adhesion, however, was almost completely inhibited in the absence of CalDAG-GEFI (Fig.
5B,C), confirming the key role of this molecule in the regulation of the adhesive properties
of platelets.
Discussion
In this study, we compared platelet activation in mice with a conditional deletion of STIM1
in platelets/megakaryocytes and mice lacking CalDAG-GEFI. CalDAG-GEFI senses
increased intracellular Ca2+ concentrations and triggers various cellular responses via the
activation of the small GTPase Rap1. STIM1 was shown to be important for store-operated
calcium entry in platelets and its deletion in mice led to protection from injury-induced
thrombosis, presumably due to a defect in the adhesive function of STIM1-deficient platelets
[21]. By contrast, our studies demonstrate that STIM1 is not critical for platelet aggregation
both under static and flow conditions, while it plays an important role for the platelet pro-
coagulant response.
Our studies confirm STIM1 as a crucial molecule in SOCE in platelets. When looking at
aggregation and thrombus formation of STIM1-deficient platelets, we observed similarities
and discrepancies to previous studies. In accordance with Varga-Szabo et al. [21], we found
the most prominent defects in integrin αIIbβ3 activation upon stimulation of STIM1-
deficient cells via GPVI. On a molecular level, GPVI-mediated αIIbβ3 activation in Stim1fl/fl
Pf4-Cre platelets was reduced by ~50% when compared to controls. Given the high number
of αIIbβ3 receptors on the platelet surface, however, this defect in activation had no effect
on the ability of these cells to aggregate in vitro. Defects in aggregation were only observed
in Stim1fl/fl Pf4-Cre platelets activated with threshold concentrations of collagen or collagen-
related peptides, but not the more potent GPVI agonist, convulxin. Consistent with this
minor defect in aggregation, we observed normal adhesion and thrombus formation of
Stim1fl/fl Pf4-Cre platelets perfused over a collagen surface at arterial or venous shear rates.
In contrast, platelets lacking CalDAG-GEFI showed marked defects in aggregation and
thrombus formation under flow. Thus, in contrast to previous studies [21, 23], our studies
suggest only a minor role for STIM1 in platelet aggregation. One potential explanation for
the different phenotypes comes from methodological differences between the studies. For
example, the microfluidic devices used for the respective studies are custom-made and thus
may generate slightly different flow patterns. Variation may also derive from differences
between the collagen preparations and the collagen coating procedures used to generate the
pro-thrombotic surface. Arguably the most obvious difference between these studies,
however, is the difference in strategies to delete STIM1 in platelets/mice. Both Varga-Szabo
et al. and Gilio et al. used chimeric mice with a complete knockout of STIM1 in all blood
cells. In our study, we used mice with a conditional deletion of Stim1 in the platelet/
megakaryocyte lineage. There are drawbacks to both systems: the chimeric mice lack
STIM1 in all blood cells, a potential limitation in assays monitoring thrombosis in whole
blood. Furthermore, lethal irradiation required for the generation of chimeric mice causes
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the systemic release of inflammatory mediators [30], which may adversely affect circulating
platelets [31]. The platelet-specific, conditional deletion of STIM1 described here eliminates
the above-mentioned complications. While deletion by the Cre recombinase can be
incomplete, we did not detect significant amounts of STIM1 in lysates from Stim1fl/fl Pf4-
Cre platelets, and intracellular staining for STIM1 was absent in >95% of circulating
platelets, confirming the virtually complete deletion of β1 integrin in the initial description
of the Pf4-Cre transgenic mice [29].
In contrast to the retained pro-adhesive function of STIM1-deficient platelets, PS exposure
was markedly impaired in Stim1fl/fl Pf4-Cre platelets. In our previous work, we found a
similar defect in platelet PS exposure for cells isolated from mice expressing an inactive
mutant of the STIM1-activated Ca2+ channel Orai1 [22], a finding that was confirmed for
STIM1-deficient platelets by Gilio et al. [23]. When perfused over collagen in the presence
of thrombin, however, PS exposure and fibrin generation were normal in blood from
Stim1−/− chimeras. Thus, the authors suggested that platelet SOCE could be redundant for
the formation of fibrin-rich thrombi at injury sites where thrombin is present as a co-agonist.
Our studies argue against this conclusion. In a model of thrombin-dependent, localized
thrombosis (laser injury, Fig. 5), we observed impaired formation of fibrin-rich thrombi at
sites of vascular injury. While the initial adhesion and aggregation of platelets was not
affected in arterioles of Stim1fl/fl Pf4-Cre mice, thrombi were instable and substantially
smaller than in WT controls, and fibrin formation was delayed and reduced. Thus, our
studies argue for a critical role of STIM1 and SOCE for platelet-dependent, early thrombin
generation at the site of vascular injury.
Our results are also in line with studies on the adhesive and pro-coagulant properties of
platelets isolated from patients with Scott syndrome [32–33]. Like STIM1-deficient
platelets, “Scott” platelets adhere, spread, and capture free-flowing platelets equally well as
platelets from a control subject. However, platelet PS exposure and platelet-dependent fibrin
formation is strongly impaired. Platelets from Scott patients are severely impaired in their
ability to express PS in response to elevated [Ca2+]i, probably due to a defect in calcium-
dependent phospholipids scrambling by transmembrane protein 16F (TMEM16F) [7]. The
identification of calcium-dependent phospholipid scramblases like TMEM16F may suggest
that PS exposure simply requires sustained elevated [Ca2+]i but is independent of
intracellular signaling. Our studies, however, do not support this hypothesis as PS exposure
in activated platelets was dependent on signaling via CalDAG-GEFI and P2Y12 (Fig. 4C),
confirming studies in human platelets, which also identified a role for P2Y12 in the pro-
coagulant response of platelets [34]. The complete inhibition of PS exposure observed in
P2Y12 inhibitor-treated CalDAG-GEFI−/− platelets suggests that PS exposure in platelets
depends on signaling by Rap1. It is currently not clear how one molecule, Rap1, can
regulate diverse cellular functions such as integrin-mediated adhesion and pro-coagulant
response. Interestingly, we observed similar defects in PS exposure in STIM1-deficient and
CalDAG-GEFI-deficient platelets, suggesting that sustained elevated [Ca2+]i in platelets is
particularly important for the pro-coagulant role of the CalDAG-GEFI/Rap1 signaling
module. Furthermore, our studies with platelets activated in the presence of the P2Y12
inhibitor 2-MeSAMP provide an explanation for the limited contribution of STIM1/SOCE to
platelet aggregation. Compared to cells activated in the absence of the P2Y12 inhibitor,
Stim1fl/fl Pf4-Cre platelets activated in the presence of 2-MeSAMP showed a marked defect
in integrin activation and aggregation. Thus, sustained calcium signaling via SOCE is
critical for integrin-mediated aggregation in the absence of P2Y12 signaling, mediated via
CalDAG-GEFI. Under normal conditions, however, SOCE is not critical for platelet
aggregation as Ca2+ from intracellular stores triggers CalDAG-GEFI-dependent Rap1/
integrin activation, which is sustained via signaling by P2Y12.
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In summary, our studies in mice with a conditional deletion of STIM1 in platelets/
megakaryocytes demonstrate that STIM1/SOCE plays a crucial role for the conversion of
platelets from a pro-adhesive to a pro-coagulant state. Our studies demonstrate that STIM1
is not critical for the pro-adhesive function of platelets, while it is required for platelet PS
exposure in vitro and platelet-dependent thrombin/fibrin formation at sites of vascular
injury. In contrast, CalDAG-GEFI is critical for both platelet accumulation at sites of
vascular injury and the conversion to a pro-coagulant state.
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Figure 1. Specific deletion of STIM1 in platelets
(A) Western blot for STIM1 in platelet lysates from Stim1fl/fl and Stim1fl/fl Pf4-Cre mice
(two samples each). (B) Intracellular staining for STIM1 in Mac1-positive leukocytes (left
panel) or platelets (middle panel) from Stim1fl/fl (black line) and Stim1fl/fl Pf4-Cre (grey line)
mice. Platelets were stained for von Willebrand factor (VWF) as a control (right panel). (C)
Stim1fl/fl (black) and Stim1fl/fl Pf4-Cre (grey) platelets were loaded with the calcium sensing
dye Fluo-4 and treated with thapsigargin (TG) in the absence of extracellular Ca2+. Ca2+
influx was induced by addition of 0.5 mM CaCl2 to the buffer solution.
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Figure 2. Role of CalDAG-GEFI and STIM1 for integrin-mediated platelet aggregation
Integrin-mediated aggregation of Stim1fl/fl (black line), Stim1fl/fl Pf4-Cre (grey line), and
CalDAG-GEFI−/− (dotted line) platelets in response to threshold concentrations of the
indicated agonists. Traces are representative of 5 independent experiments.
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Figure 3. Role of CalDAG-GEFI and STIM1 for thrombus formation on collagen under flow
conditions
Anticoagulated whole blood from Stim1fl/fl, Stim1fl/fl Pf4-Cre, or CalDAG-GEFI−/− mice
was perfused over collagen at venous or arterial shear rates. Platelet adhesion and surface PS
exposure were detected by staining with anti-GpIX-Alexa488 (green) and annexin V-
Alexa647 (red). (A) Representative images taken at the indicated time points during the
perfusion at arterial shear rates. (B) Mean fluorescence intensity measured over time ±
SEM; n = 10. Stim1fl/fl: black line; Stim1fl/fl Pf4-Cre: red line (C) Surface area covered by
platelets at the end of the perfusion period (presented as % of surface area covered by
collagen ± SEM; n = 10). Stim1fl/fl: black bars; Stim1fl/fl Pf4-Cre: grey bars
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Figure 4. STIM1 and CalDAG-GEFI are critical for Ca2+-dependent PS exposure in activated
platelets
(A) Number of annexin V-positive cells detected at the end of the perfusion over collagen at
arterial shear rates (% ± SEM). The number of annexin V-positive platelets in Stim1fl/fl
blood after 5 min of perfusion was defined as 100%; n = 10. (B, C) PS exposure on platelets
activated under static conditions. Stim1fl/fl (squares), Stim1fl/fl Pf4-Cre (circles), and
CalDAG-GEFI−/− (triangles) platelets were stimulated with the combination of PAR4p (0.1
mM) and Cvx (indicated concentrations) for 10 minutes under static conditions, stained with
annexin V-Alexa647, and immediately analyzed. The studies were done in the presence and
absence of 100 µM 2-MeSAMP, an inhibitor of P2Y12. Results are expressed as % ± SEM
with the number of annexin V-positive Stim1fl/fl platelets activated with 300 ng/ml Cvx
defined as 100%; n = 10. *p<.05, **p<0.005, ***p<0.0001.
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Figure 5. Impaired platelet adhesion and fibrin accumulation in arterioles of Stim1fl/fl Pf4-Cre
and CalDAG-GEFI−/− mice
Mice were injected with Alexa488-labeled Fab fragments to αIIbβ3 (MWReg30) and
Alexa647-labeled antibodies to fibrin. (A, B) Changes in fluorescence intensity over time
measured after laser injury in cremaster muscle arterioles of Stim1fl/fl Pf4-Cre (A) and
CalDAG-GEFI−/− (B) mice. Results represent the mean fluorescence intensity ± SEM
measured in 3 independent experiments (n = 12–18 vessels for each group). (C)
Representative images (Green-platelets; Red-Fibrin). See supplemental Videos 1–3 for a
better visualization of the differences in thrombus growth and stability observed in the
respective study groups. *p<0.05, **p<0.005.
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Table 1
Surface expression of GPVI, GPIX, αIIbβ3 and β1 integrin in Stim1fl/fl and Stim1fl/fl Pf4-Cre platelets. Data





IgG 7.9 ± 0.2 8.1 ± 0.4
GPVI 185.3 ± 10.8 186.5 ± 3.8
GPIX 693.2 ± 82.3 706.2 ± 121.3
αIIbβ3 2287.8 ± 207.9 2188 ± 194.5
β1 575.2 ± 38.6 584.8 ± 45.9
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Table 2
Expression levels of fibrinogen, von Willebrand factor (VWF) and P-selectin in Stim1fl/fl and Stim1fl/fl Pf4-Cre






IgG 2.0 ± 0.1 2.3 ± 0.2
fibrinogen 100.9 ± 7.1 118.8 ± 14.3
VWF 55.5 ± 4.2 60.7 ± 6
P-selectin 11.3 ± 0.4 12.6 ± 1.1
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